Candel Therapeutics, Inc. Financials

Candel Therapeutics, Inc. (CADL) has a return on equity of -73.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Candel Therapeutics, Inc. (CADL) recorded an outflow of $38.9M in free cash flow during fiscal year 2025. This represents a -43.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Candel Therapeutics, Inc. (CADL) recorded an outflow of $38.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Candel Therapeutics, Inc. (CADL) had $125.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Candel Therapeutics, Inc. (CADL) invested $587K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Candel Therapeutics, Inc. (CADL) invested $30.5M in research and development during fiscal year 2025.

Candel Therapeutics, Inc. (CADL) had 73M shares outstanding as of fiscal year 2025.

Candel Therapeutics, Inc. (CADL) had a current ratio of 13.49 as of fiscal year 2025, which is generally considered healthy.

Candel Therapeutics, Inc. (CADL) had a debt-to-equity ratio of 1.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Candel Therapeutics, Inc. (CADL) had a return on assets of -30.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2025, Candel Therapeutics, Inc. (CADL) held $119.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $38.3M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Candel Therapeutics, Inc. (CADL) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Candel Therapeutics, Inc. (CADL) reported a net loss of $38.2M while operations used $38.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Candel Therapeutics, Inc. (CADL) reported an operating loss of $48.3M against $2.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.